Search

Displaying results 3881 - 3890 of 4231 in total
  1. Drug

    Guvacine

    go.drugbank.com/drugs/DB08848
    Experimental

    Guvacine is a pyridine alkaloid found in the Areca nut (also known as the Betel nut). It is an experimental drug with no approved indication.

  2. Drug

    Gaboxadol

    go.drugbank.com/drugs/DB06554
    Investigational

    Gaboxadol also known as 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol (THIP) is an experimental sleep aid drug developed by Lundbeck and Merck, who reported increased deep sleep without the reinforcing

  3. Drug

    Geneticin

    go.drugbank.com/drugs/DB04263
    Experimental

    Geneticin (also known as G418) is an aminoglycoside antibiotic similar in structure to gentamicin B1, produced by Micromonospora rhodorangea.

  4. Drug

    Anti-SARS-CoV-2 immunoglobulin

    go.drugbank.com/drugs/DB16360
    Investigational

    from [COVID-19 convalescent plasma](https://go.drugbank.com/drugs/DB15692) but contains more SARS-CoV-2 neutralizing antibodies than found in [convalescent plasma](https://go.drugbank.com/drugs/DB15692) as

  5. Drug

    ChulaCov19 mRNA vaccine

    go.drugbank.com/drugs/DB16445
    Experimental

    The ChulaCov19 vaccine is mRNA-based and was developed in Thailand’s Chulalongkorn University in collaboration with the University of Pennsylvania in the US[L30673, L30678].

  6. Drug

    LV-SMENP Vaccine

    go.drugbank.com/drugs/DB15804
    Experimental

    As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials.

  7. Drug

    Esmirtazapine

    go.drugbank.com/drugs/DB06678
    Investigational

    Merck has terminated its internal clinical development program for esmirtazapine as of March 2010.

  8. Drug

    Vadimezan

    go.drugbank.com/drugs/DB06235
    Investigational

  9. Drug

    NLX-P101

    go.drugbank.com/drugs/DB05924
    Experimental

    NLX-P101 is being evaluated as a therapeutic drug when injected into this deep brain structure that is known to function abnormally in Parkinson’s patients.

  10. Drug

    TTP889

    go.drugbank.com/drugs/DB05131
    Investigational

    TTP889, an orally bioavailable selective inhibitor of the intrinsic coagulation pathway, is being developed as an anticoagulant for the treatment of thromboembolic disorders.